Request Trial
tobias-wuttke_bardehle-pagenberg_8827_810
10 January 2023Muireann Bolger

Bardehle Pagenberg boosts litigation team with senior hire

German IP specialist gears up for UPC with experienced partner | Patent litigator previously led practice at IP boutique Meissner Bolte.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
‘When a UPC judge wears their robe, they have no gender’
9 June 2026   In the second of a series of interviews with women judges at the Unified Patent Court, Carine Gillet shares her views with Sarah Speight on encouraging more women into technical judicial careers, how equipped the court is to handle life sciences disputes, and more.
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026   A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.
Careers
Clarivate’s new IP president to ‘usher in next phase of growth’
9 June 2026   The data and intelligence firm appoints the former CEO of CPA Global—which Clarivate bought in 2020—to lead the IP division’s growth, as the global company aims to accelerate AI integration and streamline its core business operations.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

‘When a UPC judge wears their robe, they have no gender’
Hikma v Amarin: Six takeaways from the pivotal ruling
Clarivate’s new IP president to ‘usher in next phase of growth’
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
Ex-Kirkland patent litigator jumps to rival firm
Hikma triumphs at SCOTUS in landmark skinny-label ruling
Pfizer strikes $10.5 billion oncology deal with Chinese biotech
Dehns appoints head of litigation following wave of senior hires